Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More
Ikena Oncology gets FDA fast track designation for IK-930 in mesothelioma
Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. ... Read More
BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More
Dr. Reddy’s subsidiary Aurigene signs $438m licensing deal with Olema
Dr. Reddy’s Laboratories said that its fully-owned subsidiary Aurigene Discovery Technologies has signed an exclusive global collaboration and license agreement worth up to $438 million ... Read More
Cullinan Oncology to sell Cullinan Pearl to Taiho Pharmaceutical for $275m
American biopharma company Cullinan Oncology has agreed to sell its subsidiary Cullinan Pearl to Taiho Pharmaceutical, a Japanese specialty pharma company, for $275 million. Cullinan ... Read More
GSK to acquire US biopharma company Sierra Oncology for $1.9bn
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9 billion (£1.5 billion). As per the terms ... Read More
Halozyme Therapeutics to acquire specialty pharma company Antares Pharma for $960m
Halozyme Therapeutics, a California-based publicly-listed biotech company, has agreed to acquire New Jersey-based specialty pharma company Antares Pharma for around $960 million with an objective ... Read More
Adagene, Sanofi signs collaboration and license deal worth up to $2.5bn
Adagene, a US-based biopharma company, has signed a collaboration and license deal worth up to $2.5 billion plus royalties with Sanofi to produce masked monoclonal ... Read More
Zai Lab treats first patient in China in PANOVA-3 trial of TTFields
Zai Lab Limited said that it has treated the first patient in Greater China in the PANOVA-3 phase 3 clinical trial of tumor treating fields ... Read More
Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial
Alphamab Oncology said that it has completed enrolling patients in China for its KN026-203 phase 2 clinical trial of the combination of KN026 and KN046 ... Read More